Prevalence of metabolic syndrome in Japanese type 2 diabetic patients and its significance for chronic vascular complications

Diabetes Research and Clinical Practice

Volumn 79, Issue 2, 2008, Pages 310-317

  Shimajiri, Yoshinori ^a   Tsunoda, Keiko ^b   Furuta, Machi ^a   Kadoya, Yoshiki ^c   Yamada, Shyoichi ^c   Nanjo, Kishio ^a   Sanke, Tokio ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Kawakita General Hospital   (Japan)

^c Fuchu Hospital   (Japan)

Author keywords

Chronic diabetic complications; Metabolic syndrome; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C PEPTIDE; C REACTIVE PROTEIN;

ADULT; ARTERY DISEASE; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR RISK; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PREVALENCE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

AGE OF ONSET; AGED; BODY MASS INDEX; C-PEPTIDE; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; VASCULAR DISEASES;

EID: 38349178608     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.08.026     Document Type: Article

References (38)

1. World Health Organization. Definition, Diagnosis, and Classification of Diabetes and its Complications: Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus (1999), World Health Organization, Geneva, Switzerland
2. Anon. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: executive summary of the third of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel III). JAMA 285 (2001) 2486-2497
3. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
4. Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 149 (1989) 1514-1520
5. DeFronzo R.A., and Ferrannini. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
6. Nakamura T., Tsubono Y., Kameda-Takemura K., Funahashi T., Yamashita S., Hisamichi S., et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Circ. J. 65 (2001) 11-17
7. Balkau B., et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 28 (2002) 364-376
8. Einborn D., Reaven G.M., Cobin R.H., Ford E., Ganda O.P., Handelsman Y., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9 (2003) 237-252
9. International Diabetes Federation Press Conference, The IDF consensus worldwide definition of the metabolic syndrome [article on line], 2005. Available from http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf.
10. Study Group for Definition of Metabolic Syndrome. Definition and diagnostic criteria of metabolic syndrome. J. Jpn. Soc. Intern. Med. 94 (2005) 188-203
11. Yeo W.W., and Yeo K.R. Predicting CHD risk in patients with diabetes mellitus. Diabet. Med. 18 (2001) 341-344
12. Song S.H., and Brown P.M. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet. Med. 21 (2004) 238-245
13. McEwan P., Williams J.E., Griffiths J.D., Bagust A., Peters J.R., Hopkinson P., et al. Evaluating the performance of the Framimgham risk equations in a population with diabetes. Diabet. Med. 21 (2004) 318-323
14. Nakamura T., Tsubono Y., Kameda-Takemura K., Funahashi T., Yamashita S., Hisamichi S., et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Jpn. Circ. J. 65 (2001) 11-17
15. Furuta M., Tamai M., Hanabusa T., Yamamoto Y., Nanjo K., and Sanke T. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients. Diabetes Res. Clin. Pract. 72 (2006) 302-307
16. Tsunoda K., Arita M., Yukawa M., Ueyama M., Furuta M., Nakagawa T., et al. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type 2 diabetic patients. J Diabetes Complications 19 (2005) 123-127
17. Inomata S., Haneda M., Moriya T., Katayama S., Iwamoto Y., Sakai H., et al. Revised criteria for the early diagnosis of diabetic nephropathy. J. Jpn. Diab. Soc. 48 (2005) 757-759
18. Treatment Guide for Diabetes, Japan Diabetes Society, Bunkodo, Tokyo, Japan, 2007, p. 66.
19. Takeuchi H., Saitoh S., Takagi S., Ohnishi H., Ohhata J., Isobe T., et al. Metabolic syndrome and insulin resistance in Japanese males-Tanno-Soubetsu study. J. Jpn. Diab. Soc. 46 (2003) 739-744
20. Miyawaki T., Hirano M., Moriyama K., Sasaki Y., Aono H., Saito N., et al. Metabolic syndrome in Japanese diagnosed with visceral fat measurement by computed tomography. Proc. Jpn. Acad. 81 (2005) 1-9
21. Hara K., Matsushita Y., Horikoshi M., Yokoyama T., Tanaka H., and Kadowaki T. A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population. Diabetes Care 29 (2006) 1123-1124
22. Sone H., et al. The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions. Diabetes Care 29 (2006) 145-147
23. Sone H., et al. Effects of lifestyle modifications on patients with type 2 diabetes. The Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm. Metab. Res. 34 (2002) 509-515
24. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP): NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participant age 50 years and older. Diabetes 52 (2003) 1210-1214
25. Ilanne-Parikka P., et al. Prevalence of the metabolic syndrome and its components. Findings from a Finnish general population sample and the diabetes prevention study cohort. Diabetes Care 27 (2004) 2135-2140
26. Bruno G., Merletti F., Biggeri A., Bargero G., Ferrero S., Runzo C., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes. Diabetes Care 27 (2004) 2689-2694
27. Bonaro E., Targher G., Formentini G., Calcaterra F., Lombardi S., Marini F., et al. Metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from Verona Diabetes Complications Study. Diabet. Med. 21 (2004) 52-58
28. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
29. Sone H., et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 28 (2005) 1463-1471
30. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
31. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
32. Lahoz C., Garcia-Iglesias M.F., Vicente I., Taboada M., Laguna F., and Mostaza J. Metabolic syndrome and asymptomatic peripheral artery disease in subjects over 60 years of age. Diabetes Care 29 (2006) 148-150
33. Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study group. EURODIAB controlled trail of lisinopril in insulin dependent diabetes mellitus. Lancet 351 (1998) 28-31
34. Stølie A.K., Porta M., Parving H.H., Bilous R., and Klein R. The diabetic retinopathy candesartan trials (DIRECT) programme; baseline characteristics. J. Renin Angiotensin Aldosterone Syst. 6 (2005) 25-32
35. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329 (1993) 1456-1462
36. Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., and Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 128 (1998) 982-988
37. Baba S., and J-MIND Study Group. Nifedipine and analapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res. Clin. Pract. 54 (2001) 191-201
38. Weiner D.F., Tighiouart H., Amin M.G., Stark P.C., MacLeod B., Griffith J.L., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 15 (2004) 1307-1315